Low-risk prostate cancer patient: active treatment.

Published

Journal Article (Review)

We currently lack a prospective, randomized, multicenter trial, to reassure low-risk prostate cancer patients, especially younger ones, that watchful waiting is a legitimate treatment. To better manage these patients, we need to: first, confirm that the patient has low-risk prostate cancer; second, adapt the treatment to the risk (i.e., if therapy is chosen over watchful waiting, it should be monotherapy not multiple therapy); third, be aware of age migration; fourth, know that radical prostatectomy and radiation were shown to be very effective for these patients at 10-year follow-up; and lastly, make an effort to better define watchful waiting and embrace it more, to avoid overtreatment.

Full Text

Duke Authors

Cited Authors

  • Moul, JW; Saad, F

Published Date

  • June 2005

Published In

Volume / Issue

  • 12 Suppl 2 /

Start / End Page

  • 25 - 27

PubMed ID

  • 16018829

Pubmed Central ID

  • 16018829

International Standard Serial Number (ISSN)

  • 1195-9479

Language

  • eng

Conference Location

  • Canada